| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
65 |
| Employees |
450 |
| Revenues (TTM) (Millions $) |
38 |
| Net Income (TTM) (Millions $) |
-726 |
| Cash Flow (TTM) (Millions $) |
-40 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Mirati Therapeutics Inc. is a biopharmaceutical company that specializes in the development of targeted oncology therapeutics. The company focuses on developing drugs that target genetic and molecular alterations in cancer cells, with the aim of improving the outcomes for patients with cancer.
Mirati Therapeutics uses precision medicine approaches to identify and develop therapies for specific patient populations, particularly those with genetically-defined cancers. The company's pipeline includes both small molecule inhibitors and immuno-oncology treatments.
Mirati Therapeutics is known for its lead product candidate, adagrasib (MRTX849), which targets KRAS G12C mutations, a key driver of various types of cancer. The company is conducting clinical trials to evaluate the safety and efficacy of adagrasib in multiple cancer types.
In addition to adagrasib, Mirati Therapeutics is also working on other programs targeting specific genetic alterations, including codon 68 mutations in KRAS and exon 20 insertions in EGFR.
Overall, Mirati Therapeutics Inc. is dedicated to advancing precision oncology treatments and improving the lives of cancer patients by developing innovative therapies that target the underlying genetic and molecular drivers of cancer.
Company Address: 3545 Cray Court, San Diego, 92121 CA
Company Phone Number: 332-3410 Stock Exchange / Ticker: NASDAQ MRTX
|
%
